A Double-Blind Trial of Ticlopidine in Sickle Cell Disease

Summary

Baseline studies of ¹¹¹indium oxine labelled platelet life-span, platelet α-granule release products, β-thromboglobulin (βTG) and platelet factor 4 (PF4), and factor VIII related activities were performed on 9 asymptomatic patients with sickle cell disease, who were subsequently randomised in a prospective double-blind trial of ticlopidine (250 mg. b. d.) or placebo for one month and the investigations repeated. Control studies indicated that 5 of the 9 patients had shortened platelet survivals: mean βTG (50.8 ng/ ml) and PF4 (19.5 ng/ml), factor VIII: C (283.4 i. u./dl) and factor VIIIR: AG (168.7 u/dl) levels were raised. Ticlopidine treatment did not significantly improve platelet life-span or factor VIII levels, though it was associated with reduced values of βTG and PF4. One patient taking ticlopidine developed an infarctive sickle crisis. Although ticlopidine blocked platelet activation, this alone did not improve platelet survival or prevent sickle crisis: in view of evidence of platelet activation in sickle cell disease, however, a longer trial of prophylactic antiplatelet drugs might be warranted.

Keywords

Sickle cell disease - Platelet survival - Ticlopidine - β-thromboglobulin - Platelet factor 4

• References

• 1 Richardson SG N, Matthews KB, Stuart J, Geddes AM, Wilcox RM. Serial changes in coagulation and viscosity during sickle cell crisis. Br J Haematol 1979; 41: 95-103
• 2 Leslie J, Langler D, Serjeant GR, Serjeant BE, Desai P, Gordon YB. Coagulation changes during the steady state in homozygous sicklecell disease in Jamaica. Br J Haematol 1975; 30: 159-166
• 3 Leichtman DA, Brewer GJ. Elevated plasma levels of fibrinopeptide A during sickle cell anaemia pain crisis - evidence for intravascular coagulation. Am J Hematol 1978; 5: 183-190
• 4 Alkjaersig N, Fletcher A, Joist H, Chaplin Jr H. Hemostasis alterations accompanying sickle cell pain crises. J Lab Clin Med 1976; 88: 440-449
• 5 Ittyerah R, Alkjaersig N, Fletcher A, Chaplin H. Coagulation factor XIII concentration in sickle cell disease. J Lab Clin Med 1976; 99: 546-554
• 6 Murphy RC, Shapiro S. The pathology of sickle cell disease. Ann Intern Med 1945; 23: 376-397
• 7 Mann JR, Deeble TJ, Breeze GR, Stuart J. Ancrod in sickle cell crisis. Lancet 1972; 1: 934-937
• 8 Salvaggio JE, Arnold CA, Banov CH. Long-term anticoagulation in sickle-cell disease. N Engl J Med 1963; 269: 182-186
• 9 Chaplin Jr H, Alkjaersig N, Fletcher AP, Michael JM, Joist JH. Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises. Thromb Haemostas 1980; 43: 218-221
• 10 de Gramont A, Canuel C, Krulik M, Bauters F, Degos L, Marty M, Najean Y. Toxicite hématologique de la ticlopidine. Nouv Rev Fr Hematol 1982; 24: 35-37
• 11 Chomienne C, Baumelou E, Rio B, Peuchavy C, Stanek L, Samama M, Zittoun R. Deux observations d’une granulocytose aiguë au cours d’un traitement anti-agrégant par la ticlopidine. Rev Med Ther 1983; 24: 589-590
• 12 Hawker RJ, Hawker LM, Wilkinson AR. Indium (¹¹¹In)-labelled human platelets: optimal method. Clin Sci 1980; 58: 243-248
• 13 Panel on diagnostic application of radioisotopes in Haematology. Recommended methods for radioisotope platelet survival studies. Blood 1977; 50: 1137-1144
• 14 Bolton AE, Ludlam CA, Moore S, Pepper DS, Cash JD. Three approaches to the radioimmunoassay of human β-thromboglobulin. Br J Haematol 1976; 33: 233-238
• 15 Ludlam CA, Cash JD. Studies on the liberation of β-thromboglobulin from human platelets in vivo. Br J Haematol 1976; 33: 239-247
• 16 Hardisty RM, Macpherson JC. A one-stage factor VIII (anti- haemophilic globulin) assay and its use on venous and capillary plasma. Thrombos Diathes Haemorrh 1962; 7: 215-229
• 17 Laurell C-B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 18 Haut MJ, Cowan DH, Harris JW. Platelet function and survival in sickle cell disease. J Lab Clin Med 1973; 82: 44-53
• 19 Heyns Adu P, Lötter MG, Badenhorst PN, ven Reenen OR, Pieters H, Minnaar PC, Retief FP. Kinetics, distribution and sites of destruction of ¹¹¹Indiumlabelled human platelets. Br J Haematol 1980; 44: 269-280
• 20 Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 1980; 33: 622-625
• 21 Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle cell anaemia. N Engl J Med 1969; 281: 923-926
• 22 duP HeynsA, Lötter MG, Badenhorst PN, van Reenen O, Pieters H, Minnaar PC. Kinetics and fate of ¹¹¹Indium-oxine labelled blood platelets in asplenic subjects. Thromb Haemostas 1980; 44: 100-104
• 23 Morgan AG, Sergeant GR. Renal function in patients over 40 with homozygous sickle-cell disease. Br Med J 1981; 282: 1181-1183
• 24 Kurihara Y, Nakayama H, Nakagawa S. Plasma β-thromboglobulin and platelet factor 4 in renal insufficiency. Thromb Res 1980; 18: 557-560
• 25 Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
• 26 Lips JP M, Sixma JJ, Schiphorst ME. The effect of ticlopidine administration to humans on the binding of adenosine diphosphate to blood platelets. Thromb Res 1980; 17: 19-27
• 27 Ashida S, Abiko Y. Effect of ticlopidine and acetyl salicylic acid on generation of prostaglandin I₂-like substance in rat arterial tissue. Thromb Res 1978; 13: 901-908
• 28 Stuart MJ, Sills RH. Deficiency of plasma prostacyclin or PGI₂ . Regenerating ability in sickle cell anaemia Br J Haematol 1981; 48: 545-550
• 29 Kenny MW, Meakin M, Worthington DJ, Stuart J. Erythrocyte deformability in sickle-cell crisis. Br J Haematol 1981; 49: 103-109
• 30 Hebbel RP, Boogaerts MA B, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anaemia. N Eng J Med 1980; 302: 992-995